Neurotech International Ltd. (AU:NTI) has released an update.
Neurotech International Ltd, a biopharmaceutical company specializing in paediatric neurological disorders, announced its participation in the Investor Verse Biotech Workshop, with a focus on sharing developments and achievements in their clinical trials. The live presentation by Executive Director Dr. Thomas Duthy can be accessed via a Zoom meeting for shareholders, investors, and interested parties. The company, known for its promising trial results in Autism Spectrum Disorder and other conditions, continues to engage the investment community with its latest research and clinical progress.
For further insights into AU:NTI stock, check out TipRanks’ Stock Analysis page.
